keyword
MENU ▼
Read by QxMD icon Read
search

anthracycline induced cardiomyopathy

keyword
https://www.readbyqxmd.com/read/27861187/genetic-testing-in-cardiomyopathies-an-update-on-indications-and-benefits
#1
Natasha Aleksova, Julie Rutberg, Martin Green, Haissam Haddad
PURPOSE OF REVIEW: As rapid genetic testing has become increasingly accessible in a timely fashion, more genetic mutations are identified in inherited conditions such as cardiomyopathies. Understanding when to consider genetic testing is an important part of the management of patients whose presentations vary from decompensated heart failure to sudden cardiac death. RECENT FINDINGS: We describe the benefits of genetic testing for risk stratification of family members, prognostication of probands, and identification of novel disease-causing mutations and examine the possible role of genetic predisposition in seemingly acquired cardiomyopathies such as peripartum and anthracycline-induced cardiomyopathy...
November 18, 2016: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/27858859/risk-factors-of-trastuzumab-induced-cardiotoxicity-in-breast-cancer-a-meta-analysis
#2
Zeeshan Jawa, Ruth M Perez, Lydia Garlie, Maharaj Singh, Rubina Qamar, Bijoy K Khandheria, Arshad Jahangir, Yang Shi
BACKGROUND: Trastuzumab targets the human epidermal growth factor receptor 2 oncogene and in combination with first-line therapy results in significantly improved survival outcomes and has thus become standard of care in both adjuvant and metastatic settings. While it is estimated that 1% to 4% of patients treated with trastuzumab will develop heart failure and ∼10% will experience a reduction in left ventricular ejection fraction (LVEF), the patient risk factors associated with trastuzumab-induced cardiotoxicity (TIC) are unclear...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27852680/successful-recovery-and-allogeneic-stem-cell-transplant-following-chemotherapy-induced-severe-cardiomyopathy-literature-review-of-management-and-prognostic-factors
#3
Muhammad Asim Shahzad, Rizwan Ishtiaq, Umar Zahid, Faiz Anwer
Chemotherapy-induced cardiomyopathy is one of the major possible hazards that can result from potential cardiotoxic agents while treating cancer. Prognostic risk factors include the rate of drug administration, history of hypertension, female gender, extremes of age, previous history of mediastinal irradiation, cumulative dose and pre-existing heart disease. Close monitoring of the patients, timely diagnosis, use of well-known biomarkers including cardiac troponins, NT-ProBNP and imaging studies like 2D Echo or cardiac MRI are essential...
November 16, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27799559/vegf-b-gene-therapy-inhibits-doxorubicin-induced-cardiotoxicity-by-endothelial-protection
#4
Markus Räsänen, Joni Degerman, Tuuli A Nissinen, Ilkka Miinalainen, Risto Kerkelä, Antti Siltanen, Janne T Backman, Eero Mervaala, Juha J Hulmi, Riikka Kivelä, Kari Alitalo
Congestive heart failure is one of the leading causes of disability in long-term survivors of cancer. The anthracycline antibiotic doxorubicin (DOX) is used to treat a variety of cancers, but its utility is limited by its cumulative cardiotoxicity. As advances in cancer treatment have decreased cancer mortality, DOX-induced cardiomyopathy has become an increasing problem. However, the current means to alleviate the cardiotoxicity of DOX are limited. We considered that vascular endothelial growth factor-B (VEGF-B), which promotes coronary arteriogenesis, physiological cardiac hypertrophy, and ischemia resistance, could be an interesting candidate for prevention of DOX-induced cardiotoxicity and congestive heart failure...
October 31, 2016: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/27755245/novel-insights-in-pathophysiology-of-antiblastic-drugs-induced-cardiotoxicity-and-cardioprotection
#5
Martino Deidda, Rosalinda Madonna, Ruggiero Mango, Pasquale Pagliaro, Pier P Bassareo, Lucia Cugusi, Silvio Romano, Maria Penco, Francesco Romeo, Giuseppe Mercuro
Despite advances in supportive and protective therapy for myocardial function, heart failure caused by various clinical conditions, including cardiomyopathy due to antineoplastic therapy, remains a major cause of morbidity and mortality. Because of the limitations associated with current therapies, investigators have been searching for alternative treatments that can effectively repair the damaged heart and permanently restore its function. Damage to the heart can result from both traditional chemotherapeutic agents, such as anthracyclines, and new targeted therapies, such as trastuzumab...
May 2016: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/27721532/benefits-of-antihypertensive-medications-for-anthracycline-and-trastuzumab-induced-cardiotoxicity-in-patients-with-breast-cancer-insights-from-recent-clinical-trials
#6
Katarzyna Rygiel
Advances in oncologic therapies have allowed many patients with breast cancer to achieve better outcomes and longer survival. However, this progress has been tempered by cardiotoxicity, associated with anticancer therapies, ranging from subclinical abnormalities to irreversible life-threatening complications, such as congestive heart failure or cardiomyopathy. In particular, exposure to chemotherapy (CHT), including anthracyclines and trastuzumab, can lead to cardiac dysfunction with short- or long-term consequences, among patients with breast cancer...
September 2016: Indian Journal of Pharmacology
https://www.readbyqxmd.com/read/27690233/utility-of-dexrazoxane-for-the-attenuation-of-epirubicin-induced-genetic-alterations-in-mouse-germ-cells
#7
Sabry M Attia, Sheikh F Ahmad, Mushtaq A Ansaria, Ahmed Nadeem, Othman A Al-Shabanah, Mohammed M Al-Harbi, Saleh A Bakheet
Dexrazoxane has been approved to treat anthracycline-induced cardiomyopathy and extravasation. However, the effect of dexrazoxane on epirubicin-induced genetic alterations in germ cells has not yet been reported. Thus, the aim of this study was to determine whether dexrazoxane modulates epirubicin-induced genetic damage in the germ cells of male mice. Our results show that dexrazoxane was not genotoxic at the tested doses. Furthermore, it protected mouse germ cells against epirubicin-induced genetic alterations as detected by the reduction in disomic and diploid sperm, spermatogonial chromosomal aberrations, and abnormal sperm heads...
2016: PloS One
https://www.readbyqxmd.com/read/27660573/cardio-oncology-a-focused-review-of-anthracycline-human-epidermal-growth-factor-receptor-2-inhibitor-and-radiation-induced-cardiotoxicity-and-management
#8
REVIEW
Jean Domercant, Nichole Polin, Eiman Jahangir
BACKGROUND: Cardio-oncology is a collaborative approach between cardiologists and oncologists in the treatment of patients with cancer and heart disease. Radiation and chemotherapy have played a major role in the decreased cancer-related mortality achieved in the past 2 decades. However, anthracycline-, tyrosine kinase-, and radiation-based therapies are each associated with independent cardiovascular (CV) risks, and these risks are cumulative when these therapies are used in combination...
2016: Ochsner Journal
https://www.readbyqxmd.com/read/27641650/ipsc-mscs-with-high-intrinsic-miro1-and-sensitivity-to-tnf-%C3%AE-yield-efficacious-mitochondrial-transfer-to-rescue-anthracycline-induced-cardiomyopathy
#9
Yuelin Zhang, Zhendong Yu, Dan Jiang, Xiaoting Liang, Songyan Liao, Zhao Zhang, Wensheng Yue, Xiang Li, Sin-Ming Chiu, Yuet-Hung Chai, Yingmin Liang, Yenyen Chow, Shuo Han, Aimin Xu, Hung-Fat Tse, Qizhou Lian
Mesenchymal stem cells (MSCs) can donate mitochondria and rescue anthracycline-induced cardiomyocyte (CM) damage, although the underlying mechanisms remain elusive. We determined that the superior efficiency of mitochondrial transfer by human induced-pluripotent-stem-cell-derived MSCs (iPSC-MSCs) compared with bone marrow-derived MSCs (BM-MSCs) is due to high expression of intrinsic Rho GTPase 1 (MIRO1). Further, due to a higher level of TNFαIP2 expression, iPSC-MSCs are more responsive to tumor necrosis factor alpha (TNF-α)-induced tunneling nanotube (TNT) formation for mitochondrial transfer to CMs, which is regulated via the TNF-α/NF-κB/TNFαIP2 signaling pathway...
October 11, 2016: Stem Cell Reports
https://www.readbyqxmd.com/read/27639916/-treatment-related-cardiotoxicity-in-childhood-cancer-survivors-risk-factors-and-follow-up
#10
B Fresneau, C Fayech, T Butel, N Haddy, D Valteau-Couanet, P Ou
Anthracycline-induced cardiotoxicity (ACT) is a severe complication in children and young adults that may lead to congestive heart failure. Some risk factors have been identified: high anthracycline cumulative dose, high radiation dose delivered on the cardiac area, or young age during the treatment. Primary prevention is not clearly defined in children. The dexrazoxane iron chelator seems to be interesting based on its short-term cardioprotective property in patients receiving doxorubicin-containing regimens...
September 14, 2016: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/27639686/a-matched-cohort-study-of-patients-with-end-stage-heart-failure-from-anthracycline-induced-cardiomyopathy-requiring-advanced-cardiac-support
#11
Garry R Thomas, Michael A McDonald, Jennifer Day, Heather J Ross, Diego H Delgado, Filio Billia, Jagdish W Butany, Vivek Rao, Eitan Amir, Philippe L Bedard, Paaladinesh Thavendiranathan
Anthracycline-induced cardiomyopathy (AIC) may progress to end-stage heart failure requiring mechanical circulatory support or orthotopic heart transplantation (OHT). Previous studies have described important clinical differences between AIC and nonischemic cardiomyopathy (NIC) cohorts requiring these advanced interventions. Therefore, we sought to extend this literature by comparing echocardiographic parameters, treatment strategies, and the prognosis between matched patients from these cohorts. This is a retrospective matched cohort study...
August 23, 2016: American Journal of Cardiology
https://www.readbyqxmd.com/read/27592051/ramipril-restores-ppar%C3%AE-%C3%AE-and-ppar%C3%AE-expressions-and-reduces-cardiac-nadph-oxidase-but-fails-to-restore-cardiac-function-and-accompanied-myosin-heavy-chain-ratio-shift-in-severe-anthracycline-induced-cardiomyopathy-in-rat
#12
Hana Cernecka, Gabriel Doka, Jasna Srankova, Lenka Pivackova, Eva Malikova, Kristina Galkova, Jan Kyselovic, Peter Krenek, Jan Klimas
We hypothesized that peroxisome proliferator-activated receptors (PPARs) might be involved in a complex protective action of ACE inhibitors (ACEi) in anthracyclines-induced cardiomyopathy. For purpose of study, we compared effects of ramipril on cardiac dysfunction, cardiac failure markers and PPAR isoforms in moderate and severe chronic daunorubicin-induced cardiomyopathy. Male Wistar rats were administered with a single intravenous injection of daunorubicin: 5mg/kg (moderate cardiomyopathy), or 15mg/kg (severe cardiomyopathy) or co-administered with daunorubicin and ramipril (1mg/kg/d, orally) or vehicle for 8 weeks...
August 31, 2016: European Journal of Pharmacology
https://www.readbyqxmd.com/read/27484957/noninvasive-early-detection-of-anthracycline-induced-cardiotoxicity-in-patients-with-hematologic-malignancies-using-the-phased-tracking-method
#13
Yoshiko Saito, Ikuko Susukida, Yoshiro Uzuka, Hiroshi Kanai
Anthracyclines are among the most effective and widely used anticancer drugs; however, their use is limited by serious cardiotoxicity. Early detection is necessary to prevent the high mortality rate associated with heart failure (HF). We evaluated cardiac function in 142 patients using conventional echocardiography and the phased tracking method (PTM), which was measured using the minute vibration and the rapid motion components, neither of which is recognized in standard M-mode nor in tissue Doppler imaging...
September 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27444332/the-human-amniotic-fluid-stem-cell-secretome-effectively-counteracts-doxorubicin-induced-cardiotoxicity
#14
Edoardo Lazzarini, Carolina Balbi, Paola Altieri, Ulrich Pfeffer, Elisa Gambini, Marco Canepa, Luigi Varesio, Maria Carla Bosco, Domenico Coviello, Giulio Pompilio, Claudio Brunelli, Ranieri Cancedda, Pietro Ameri, Sveva Bollini
The anthracycline doxorubicin (Dox) is widely used in oncology, but it may cause a cardiomyopathy with bleak prognosis that cannot be effectively prevented. The secretome of human amniotic fluid-derived stem cells (hAFS) has previously been demonstrated to significantly reduce ischemic cardiac damage. Here it is shown that, following hypoxic preconditioning, hAFS conditioned medium (hAFS-CM) antagonizes senescence and apoptosis of cardiomyocytes and cardiac progenitor cells, two major features of Dox cardiotoxicity...
2016: Scientific Reports
https://www.readbyqxmd.com/read/27342245/pathways-of-cardiac-toxicity-comparison-between-chemotherapeutic-drugs-doxorubicin-and-mitoxantrone
#15
REVIEW
Roberto Marques Damiani, Dinara Jaqueline Moura, Cassiana Macagnan Viau, Rafael Andrade Caceres, João Antonio Pêgas Henriques, Jenifer Saffi
Anthracyclines, e.g., doxorubicin (DOX), and anthracenediones, e.g., mitoxantrone (MTX), are drugs used in the chemotherapy of several cancer types, including solid and non-solid malignancies such as breast cancer, leukemia, lymphomas, and sarcomas. Although they are effective in tumor therapy, treatment with these two drugs may lead to side effects such as arrhythmia and heart failure. At the same clinically equivalent dose, MTX causes slightly reduced cardiotoxicity compared with DOX. These drugs interact with iron to generate reactive oxygen species (ROS), target topoisomerase 2 (Top2), and impair mitochondria...
September 2016: Archives of Toxicology
https://www.readbyqxmd.com/read/27313831/cardioprotective-potentials-of-plant-derived-small-molecules-against-doxorubicin-associated-cardiotoxicity
#16
REVIEW
Shreesh Ojha, Hasan Al Taee, Sameer Goyal, Umesh B Mahajan, Chandrgouda R Patil, D S Arya, Mohanraj Rajesh
Doxorubicin (DOX) is a potent and widely used anthracycline antibiotic for the treatment of several malignancies. Unfortunately, the clinical utility of DOX is often restricted due to the elicitation of organ toxicity. Particularly, the increased risk for the development of dilated cardiomyopathy by DOX among the cancer survivors warrants major attention from the physicians as well as researchers to develop adjuvant agents to neutralize the noxious effects of DOX on the healthy myocardium. Despite these pitfalls, the use of traditional cytotoxic drugs continues to be the mainstay treatment for several types of cancer...
2016: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/27294099/sarco-mir-friend-or-foe-a-perspective-on-the-mechanisms-of-doxorubicin-induced-cardiomyopathy
#17
Louis A Saddic, Jochen D Muehlschlegel
Anthracyclines are a class of chemotherapeutics used to treat a variety of human cancers including both solid tumors such as breast, ovarian, and lung, as well as malignancies of the blood including leukemia and lymphoma. Despite being extremely effective anti-cancer agents, the application of these drugs is offset by side effects, most notably cardiotoxicity. Many patients treated with doxorubicin (DOX), one of the most common anthracyclines used in oncology, will develop radiographic signs and/or symptoms of cardiomyopathy...
May 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/27255173/cardiotoxicity-in-anthracycline-therapy-prevention-strategies
#18
Margarida Cruz, Joana Duarte-Rodrigues, Manuel Campelo
The increasing use of anthracyclines, together with the longer survival of cancer patients, means the toxic effects of these drugs need to be monitored. In order to detect, prevent or mitigate anthracycline-induced cardiomyopathy, it is essential that all patients undergo a rigorous initial cardiovascular assessment, followed by close monitoring. Several clinical trials have shown the cardioprotective effect of non-pharmacological measures such as exercise, healthy lifestyles, control of risk factors and treatment of comorbidities; a cardioprotective effect has also been observed with pharmacological measures such as beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, statins, dexrazoxane and liposomal formulations...
June 2016: Portuguese Journal of Cardiology: An Official Journal of the Portuguese Society of Cardiology
https://www.readbyqxmd.com/read/27236517/myocardial-characterization-using%C3%A2-dual-energy-ct-in-doxorubicin-induced-dcm-comparison-with-cmr-t1-mapping-and%C3%A2-histology-in-a-rabbit-model
#19
Yoo Jin Hong, Tai Kyung Kim, Donghyun Hong, Chul Hwan Park, Sae Jong Yoo, Mary Ellen Wickum, Jin Hur, Hye-Jeong Lee, Young Jin Kim, Young Joo Suh, Andreas Greiser, Mun Young Paek, Byoung Wook Choi
OBJECTIVES: This study sought to evaluate whether patterns of myocardial change in doxorubicin-induced dilated cardiomyopathy determined using dual-energy computed tomography (CT) were similar to characterization by extracellular volume fraction (ECV) using cardiac magnetic resonance (CMR) T1-mapping and collagen volume fraction (CVF) measured using histology. BACKGROUND: Anthracycline chemoagents are effective against a wide range of malignant conditions. However, cardiotoxicity is a well-known adverse effect of these drugs...
July 2016: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/27186191/cardiotoxicity-of-anthracycline-therapy-current-perspectives
#20
Mihaela Valcovici, Florina Andrica, Corina Serban, Simona Dragan
Anthracyclines, especially doxorubicin and daunorubicin, are the drugs of first choice in the treatment of patients with hematologic malignancies, soft-tissue sarcomas, and solid tumors. Unfortunately, the use of anthracyclines is limited by their dose-dependent and cumulative cardiotoxicity. The molecular mechanism responsible for anthracycline-induced cardiotoxicity remains poorly understood, although experimental and clinical studies have shown that oxidative stress plays the main role. Hence, antioxidant agents, especially dexrazoxane, and also other drug classes (statins, β-blockers) proved to have a beneficial effect in protecting against anthracycline-induced cardiotoxicity...
April 1, 2016: Archives of Medical Science: AMS
keyword
keyword
56258
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"